9 Meters Biopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$NMTR
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $NMTR alert in real time by email
nmtr-20230612
0001551986FALSE00015519862023-06-122023-06-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
FORM 8-K
 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): June 12, 2023
 
 
 
9 Meters Biopharma, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware 001-37797 27-3948465
(State or other jurisdiction of
incorporation or organization)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
 
4509 Creedmoor Road, Suite 600, Raleigh, NC 27612
(Address of principal executive offices) (Zip Code)
 
(919) 275-1933
(Registrant’s telephone number, include area code)
 

(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock $0.0001 Par ValueNMTRThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 



Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 3.01.Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On June 12, 2023, 9 Meters Biopharma, Inc. (the “Company”) was notified by the Nasdaq Stock Market LLC (“Nasdaq”) that for the last 31 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until December 11, 2023, to regain compliance with the Bid Price Rule. If at any time before December 11, 2023, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with a written confirmation of compliance with the Bid Price Rule.

If the Company does not regain compliance with the Bid Price Rule by December 11, 2023, the Company may be eligible for an additional 180-day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary.

If the Company does not regain compliance with the Bid Price Rule when required, Nasdaq will provide written notification to the Company that its common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearings panel.

The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on the Nasdaq Capital Market under the symbol “NMTR”. The Company is currently evaluating its options for regaining compliance. There can be no assurance that the Company will regain compliance with the Bid Price Rule or maintain compliance with any of the other Nasdaq continued listing requirements.










SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    
 9 Meters Biopharma, Inc.
    
Date: June 16, 2023By: /s/ Bethany Sensenig
   Bethany Sensenig
   Chief Financial Officer
 
 
 
 

 

 
 
 


Get the next $NMTR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NMTR

DatePrice TargetRatingAnalyst
7/8/2021$5.00Outperform
BMO Capital Markets
More analyst ratings

$NMTR
Press Releases

Fastest customizable press release news feed in the world

See more
  • 9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

    RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.Mark Sirgo, Chairman of the Board of 9 Meters, stated, "On behalf of the Board of Directors, I want to thank John for his service and dedication to the Company." The Board of Directors has appointed Bethany Sensenig, Chief Financial Officer of 9 Meters, to serve as interim Chief Executive Officer in addition to her current responsibiliti

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

    RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "We are enthusiastic about the potential of vurolenatide and NM-136 to deliver value to patients. We are exploring options to fund further advancement of these assets, including financing and other strategic alternatives."Clinical Development and Business HighlightsPresentations on vurolenatide and SBS at ASPEN 2

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

    RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NMTR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NMTR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$NMTR
SEC Filings

See more

$NMTR
Leadership Updates

Live Leadership Updates

See more
  • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

    Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

    $AGRX
    $GNTA
    $NMTR
    $PG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Package Goods/Cosmetics
  • 9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

    Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer."We're very pleased to have Ms. Sensenig join the 9 Meters team as Chief Financial Officer with over twenty years of business and strategic financial leadership experience at both early-stage and large biotechnology companies," said John Temperato, President & Chief

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications

    RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications."We are very excited to have such talented individuals, each with lengthy and accomplished pharmaceutical and biotech backgrounds, join the 9 Meters team during this critical time of growth for our company," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma. "Ms. Liu's

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NMTR
Financials

Live finance-specific insights

See more
  • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022

    Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimenClinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarterRALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended Septembe

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022

    Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announcedVurolenatide End-of-Phase 2 meeting with FDA on track for 3QCash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt financing extends cash runway into 4Q 2023RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.John Temperato, President & Chief Exe

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

    On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in JuneCash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NMTR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more